[S02DA03, antipyrine, The metabolism of Procainamide can be decreased when combined with Antipyrine.]
[J01GA01, streptomycin, Streptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AA27, fingolimod, Fingolimod may increase the arrhythmogenic activities of Procainamide.]
[M03AB01, succinylcholine, The metabolism of Succinylcholine can be decreased when combined with Procainamide.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01CG01, sulbactam, Sulbactam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Procainamide.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Procainamide.]
[L02BA01, tamoxifen, The metabolism of Procainamide can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Procainamide can be decreased when combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Procainamide.]
[A04AD10, dronabinol, The metabolism of Procainamide can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Procainamide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Procainamide can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A11DA01, thiamine, The serum concentration of Procainamide can be increased when it is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Procainamide.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Procainamide.]
[N05AC02, thioridazine, The metabolism of Procainamide can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Procainamide.]
[C01BB04, aprindine, Procainamide may increase the arrhythmogenic activities of Aprindine.]
[G04BE06, moxisylyte, Moxisylyte may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AL03, tiapride, Tiapride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Procainamide can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may increase the arrhythmogenic activities of Procainamide.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA12, tobramycin, Tobramycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Procainamide can be decreased when combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Procainamide can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Procainamide.]
[S01BA05, triamcinolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Procainamide.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Procainamide.]
[D07AC02, fluclorolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Procainamide.]
[R03BA07, mometasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, Procainamide may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Procainamide may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Procainamide.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Procainamide.]
[C02BA01, trimethaphan, Procainamide may increase the neuromuscular blocking activities of Trimethaphan.]
[J01EA01, trimethoprim, The excretion of Procainamide can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Procainamide can be decreased when combined with Trimipramine.]
[R06AC04, tripelennamine, The metabolism of Procainamide can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Procainamide.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Procainamide.]
[N06AX24, vilazodone, The metabolism of Procainamide can be decreased when combined with Vilazodone.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Procainamide.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Oxyquinoline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Procainamide can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Procainamide can be increased when it is combined with Linagliptin.]
[J05AG05, rilpivirine, The metabolism of Procainamide can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Vancomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Procainamide.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Procainamide.]
[N06AX09, viloxazine, The metabolism of Procainamide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Procainamide can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Procainamide.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AA03, warfarin, Warfarin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Procainamide can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Procainamide.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Procainamide.]
[N05AF05, zuclopenthixol, The metabolism of Procainamide can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Procainamide.]
[L01EC01, vemurafenib, The metabolism of Procainamide can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Procainamide.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Procainamide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Procainamide.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Ruxolitinib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04BD07, tolterodine, The metabolism of Procainamide can be decreased when combined with Tolterodine.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Procainamide.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Procainamide.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Procainamide.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Procainamide.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H02AB11, prednylidene, The therapeutic efficacy of Procainamide can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A08AA11, lorcaserin, The metabolism of Procainamide can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Procainamide can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Procainamide can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Enzalutamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium silicate.]
[H02AA01, aldosterone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Aldosterone.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Procainamide.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Procainamide.]
[D02BA02, octinoxate, Octinoxate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Procainamide.]
[N04BD02, rasagiline, Rasagiline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Procainamide.]
[N06DA02, donepezil, The metabolism of Procainamide can be decreased when combined with Donepezil.]
[R06AC06, thonzylamine, The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Procainamide.]
[G04BD10, darifenacin, The metabolism of Procainamide can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Fludeoxyglucose (18F) may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Procainamide.]
[G04BE03, sildenafil, The metabolism of Procainamide can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Procainamide.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Procainamide.]
[C04AX11, bencyclane, Procainamide may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The metabolism of Procainamide can be decreased when combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Procainamide can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Pomalidomide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Procainamide can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A10BK02, canagliflozin, Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Procainamide.]
[A12CC09, magnesium orotate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium orotate.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Procainamide.]
[A06AX06, tegaserod, The metabolism of Procainamide can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The metabolism of Procainamide can be decreased when combined with Benzocaine.]
[L03AA12, ancestim, Ancestim may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Procainamide can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Procainamide can be decreased when combined with Everolimus.]
[A12CC05, magnesium aspartate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium aspartate.]
[N04AC01, benztropine, The metabolism of Procainamide can be decreased when combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Procainamide can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Procainamide can be decreased when combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Florbetapir (18F) may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Procainamide can be decreased when combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The serum concentration of Procainamide can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Procainamide may increase the arrhythmogenic activities of Bepridil.]
[A10BJ03, lixisenatide, Lixisenatide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Procainamide can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Procainamide can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Procainamide can be decreased when combined with Dapagliflozin.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AB04, acebutolol, Procainamide may increase the arrhythmogenic activities of Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AA32, apremilast, The metabolism of Procainamide can be increased when combined with Apremilast.]
[L02BG02, formestane, Formestane may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S03BA03, betamethasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Procainamide.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Procainamide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Procainamide.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Procainamide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Procainamide.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Procainamide.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of Cardiac Arrhythmia can be increased when Eliglustat is combined with Procainamide.]
[J01XA05, oritavancin, The metabolism of Procainamide can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CX03, methacholine, The risk or severity of adverse effects can be increased when Procainamide is combined with Methacholine.]
[N04AA02, biperiden, The metabolism of Procainamide can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Procainamide can be decreased when combined with Pirfenidone.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Procainamide.]
[J05AP09, dasabuvir, The metabolism of Procainamide can be decreased when combined with Dasabuvir.]
[B01AF03, edoxaban, Edoxaban may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Procainamide can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Procainamide can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Procainamide.]
[L01XH03, panobinostat, The metabolism of Procainamide can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Procainamide can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AA09, difemerine, The therapeutic efficacy of Difemerine can be decreased when used in combination with Procainamide.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Procainamide can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Procainamide can be decreased when combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Procainamide can be decreased when combined with Rolapitant.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Procainamide can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Idarucizumab may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Procainamide.]
[J02AC05, isavuconazole, The metabolism of Procainamide can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Procainamide.]
[L01XG03, ixazomib, Ixazomib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Procainamide.]
[M04AB05, lesinurad, Lesinurad may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Procainamide.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium Aluminum Silicate.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Procainamide.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Procainamide.]
[C03CA02, bumetanide, Bumetanide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N01BB01, bupivacaine, The metabolism of Procainamide can be decreased when combined with Bupivacaine.]
[C07AA19, bupranolol, Procainamide may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Procainamide can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Procainamide.]
[N05BE01, buspirone, The metabolism of Procainamide can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Procainamide.]
[S01GX07, azelastine, The metabolism of Procainamide can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Procainamide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Procainamide.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03CC12, bambuterol, Procainamide may increase the neuromuscular blocking activities of Bambuterol.]
[A06AH05, naldemedine, Naldemedine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Procainamide can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA02, benoxinate, Procainamide may increase the neuromuscular blocking activities of Oxybuprocaine.]
[R05DB01, benzonatate, Procainamide may increase the neuromuscular blocking activities of Benzonatate.]
[P01CA02, benznidazole, Benznidazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Procainamide can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Procainamide can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Procainamide can be increased when combined with Infliximab.]
[L01ED04, brigatinib, The excretion of Procainamide can be decreased when combined with Brigatinib.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Procainamide is combined with Bethanechol.]
[J01MA23, delafloxacin, Delafloxacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P03AC02, bioallethrin, Procainamide may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Procainamide is combined with Acetylcholine.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Procainamide can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Procainamide.]
[L01EM02, copanlisib, The excretion of Procainamide can be decreased when combined with Copanlisib.]
[L01EF03, abemaciclib, The excretion of Procainamide can be decreased when combined with Abemaciclib.]
[C07AB07, bisoprolol, The therapeutic efficacy of Procainamide can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Procainamide.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AA17, bopindolol, The metabolism of Procainamide can be decreased when combined with Bopindolol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Procainamide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Budesonide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be decreased when used in combination with Procainamide.]
[J05AX18, letermovir, The metabolism of Procainamide can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Procainamide.]
[C01AA02, acetyldigoxins, Procainamide may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Acrivastine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Captopril.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Procainamide is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Macimorelin.]
[L02BB05, apalutamide, The excretion of Procainamide can be decreased when combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AA03, camylofine, The therapeutic efficacy of Camylofin can be decreased when used in combination with Procainamide.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Procainamide.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Procainamide.]
[C07AG02, carvedilol, Procainamide may increase the arrhythmogenic activities of Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Procainamide can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, The excretion of Procainamide can be decreased when combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Procainamide can be decreased when combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01GB14, plazomicin, The excretion of Procainamide can be decreased when combined with Plazomicin.]
[C07AB08, celiprolol, Procainamide may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Procainamide can be decreased when combined with Elagolix.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Procainamide can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Procainamide can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Procainamide can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N01BA04, chloroprocaine, Procainamide may increase the neuromuscular blocking activities of Chloroprocaine.]
[D08AE05, chloroxylenol, Chloroxylenol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Procainamide.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03BB08, revefenacin, The metabolism of Procainamide can be decreased when combined with Revefenacin.]
[L04AA39, emapalumab, The metabolism of Procainamide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Procainamide.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Procainamide is combined with Amifampridine.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BG07, cifenline, Procainamide may increase the arrhythmogenic activities of Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Procainamide can be decreased when combined with Cilostazol.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Ciprofibrate.]
[S01ED05, carteolol, Procainamide may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Procainamide can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Procainamide.]
[N06BA14, solriamfetol, The excretion of Procainamide can be decreased when combined with Solriamfetol.]
[L01EN01, erdafitinib, The serum concentration of Procainamide can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Procainamide can be decreased when combined with Clobazam.]
[J01AA11, clomocycline, The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Procainamide.]
[H02AB14, cloprednol, The therapeutic efficacy of Procainamide can be decreased when used in combination with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Ubidecarenone.]
[L04AB01, etanercept, The metabolism of Procainamide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The therapeutic efficacy of Procainamide can be decreased when used in combination with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Procainamide can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03BX03, cicletanine, Procainamide may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Procainamide can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Entrectinib.]
[N07XX11, pitolisant, Procainamide may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Procainamide.]
[N04CX01, istradefylline, The metabolism of Procainamide can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The metabolism of Procainamide can be decreased when combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB01, cephalexin, The excretion of Procainamide can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DB09, cephradine, The excretion of Procainamide can be decreased when combined with Cefradine.]
[H02AB13, deflazacort, The therapeutic efficacy of Procainamide can be decreased when used in combination with Deflazacort.]
[A16AX16, givosiran, The serum concentration of Procainamide can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Golodirsen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Procainamide.]
[R06AB02, dexchlorpheniramine, The metabolism of Procainamide can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Dexpanthenol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XX72, tazemetostat, The excretion of Procainamide can be decreased when combined with Tazemetostat.]
[M01AX21, diacetylrhein, The metabolism of Procainamide can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The excretion of Procainamide can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Procainamide.]
[H02CA02, osilodrostat, The metabolism of Procainamide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Procainamide can be decreased when combined with Amprenavir.]
[R02AA03, dichlorobenzyl alcohol, Dichlorobenzyl alcohol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G03DB08, dienogest, Dienogest may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02AA08, dihydrocodeine, The metabolism of Procainamide can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Procainamide can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08CA16, clevidipine, Procainamide may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Procainamide may increase the QTc-prolonging activities of Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Procainamide.]
[L01EH03, tucatinib, The excretion of Procainamide can be decreased when combined with Tucatinib.]
[A03AA08, dihexyverine, The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Procainamide.]
[L01EX17, capmatinib, The serum concentration of Procainamide can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The metabolism of Procainamide can be decreased when combined with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX19, ripretinib, The excretion of Procainamide can be decreased when combined with Ripretinib.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX22, selpercatinib, The excretion of Procainamide can be decreased when combined with Selpercatinib.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Procainamide.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Procainamide.]
[P01BB01, proguanil, The metabolism of Procainamide can be decreased when combined with Proguanil.]
[M09AX10, risdiplam, The serum concentration of Procainamide can be increased when it is combined with Risdiplam.]
[N02AX07, oliceridine, The metabolism of Procainamide can be decreased when combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Procainamide can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The excretion of Procainamide can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The metabolism of Procainamide can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Procainamide can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Procainamide.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The metabolism of Procainamide can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Procainamide can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02BA03, choline salicylate, The serum concentration of Procainamide can be increased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, Procainamide may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Procainamide can be increased when it is combined with Berotralstat.]
[M09AA01, hydroquinine, Procainamide may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Procainamide.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V03AF12, trilaciclib, The excretion of Procainamide can be decreased when combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Procainamide.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Procainamide.]
[R03BA03, flunisolide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Flunisolide.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluocinolone acetonide.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Procainamide can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Procainamide.]
[L03AB10, peginterferon alfa-2b, The metabolism of Procainamide can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The serum concentration of Procainamide can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Procainamide.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Procainamide.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Procainamide.]
[L01XA01, cisplatin, The serum concentration of Procainamide can be increased when it is combined with Cisplatin.]
[N06AB04, citalopram, The metabolism of Procainamide can be decreased when combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Procainamide is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Technetium Tc-99m exametazime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Florbetaben (18F) may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AA04, clemastine, The metabolism of Procainamide can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Procainamide can be decreased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Procainamide can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Procainamide.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Procainamide.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Procainamide.]
[N06AA04, clomipramine, The metabolism of Procainamide can be decreased when combined with Clomipramine.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Procainamide can be decreased when combined with Clonidine.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Procainamide can be decreased when combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Procainamide.]
[N05AH02, clozapine, The metabolism of Procainamide can be decreased when combined with Clozapine.]
[J01GB12, arbekacin, Arbekacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S02DA02, cocaine, The metabolism of Procainamide can be decreased when combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Procainamide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R05DA04, codeine, The metabolism of Procainamide can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Procainamide.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AB10, hexocyclium, The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Procainamide.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Procainamide.]
[J01XB01, colistin, Colistin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Leflunomide.]
[C01BA13, hydroquinidine, Procainamide may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Procainamide.]
[A04AA03, tropisetron, Procainamide may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, The metabolism of Procainamide can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Procainamide.]
[R03BA08, ciclesonide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Procainamide.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Procainamide can be decreased when combined with Emtricitabine.]
[C05BB03, invert sugar, Invert sugar may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V08AB05, iopromide, Iopromide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V08AB07, ioversol, Ioversol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V08AB12, ioxilan, Ioxilan may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02CC05, almotriptan, The metabolism of Procainamide can be decreased when combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Procainamide.]
[S01AD03, acyclovir, The excretion of Procainamide can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Procainamide.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Procainamide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Procainamide.]
[C08CA09, lacidipine, Procainamide may increase the arrhythmogenic activities of Lacidipine.]
[N03AX09, lamotrigine, The serum concentration of Procainamide can be increased when it is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Procainamide.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Procainamide.]
[S01BA03, cortisone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, The metabolism of Procainamide can be decreased when combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Procainamide.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Magnesium carbonate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B05XA10, magnesium phosphate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium phosphate.]
[C08CA11, manidipine, Procainamide may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Mebeverine.]
[C07AA14, mepindolol, The metabolism of Procainamide can be decreased when combined with Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Procainamide can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Procainamide.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Procainamide.]
[C04AX01, cyclandelate, Procainamide may increase the arrhythmogenic activities of Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Procainamide.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Procainamide may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX07, minaprine, The metabolism of Procainamide can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Procainamide can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Procainamide can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Procainamide.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Procainamide.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Procainamide.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Procainamide.]
[M01AH05, etoricoxib, The metabolism of Procainamide can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Dantrolene.]
[C02CC04, debrisoquin, The metabolism of Procainamide can be decreased when combined with Debrisoquine.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01AA01, demeclocycline, The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Procainamide.]
[C07AB12, nebivolol, Procainamide may increase the arrhythmogenic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Procainamide can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Procainamide may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M03AC11, cisatracurium, Procainamide may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Procainamide can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Procainamide can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AA01, desipramine, The metabolism of Procainamide can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Procainamide may increase the arrhythmogenic activities of Deslanoside.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[D07XC02, desoximetasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Desoximetasone.]
[V04CH02, indigo carmine, Indigotindisulfonic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Desoxycortone.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Procainamide.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S03BA01, dexamethasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Procainamide.]
[G04BD04, oxybutynin, The metabolism of Procainamide can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Procainamide can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Procainamide.]
[L04AB04, adalimumab, The metabolism of Procainamide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Procainamide can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Procainamide can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Procainamide can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Procainamide can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The serum concentration of Procainamide can be increased when it is combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R05DA08, pholcodine, Pholcodine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AX04, pinaverium, Procainamide may increase the arrhythmogenic activities of Pinaverium.]
[A03AB14, pipenzolate, The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Procainamide.]
[L01EB02, erlotinib, The metabolism of Procainamide can be decreased when combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Procainamide.]
[D07XC04, diflucortolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Poldine can be decreased when used in combination with Procainamide.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01AA04, digitoxin, Procainamide may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Procainamide.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Procainamide.]
[H03BC01, potassium perchlorate, Potassium perchlorate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Procainamide.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Procainamide.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AB03, dimethindene, The therapeutic efficacy of Dimetindene can be decreased when used in combination with Procainamide.]
[M02AX03, dimethyl sulfoxide, The metabolism of Procainamide can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G02AD02, dinoprostone, The serum concentration of Procainamide can be increased when it is combined with Dinoprostone.]
[R06AA02, diphenhydramine, The metabolism of Procainamide can be decreased when combined with Diphenhydramine.]
[B01AC07, dipyridamole, The therapeutic efficacy of Procainamide can be decreased when used in combination with Dipyridamole.]
[A03FA02, cisapride, The metabolism of Procainamide can be decreased when combined with Cisapride.]
[N05AL04, remoxipride, The metabolism of Procainamide can be decreased when combined with Remoxipride.]
[S01AX06, resorcinol, Resorcinol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Procainamide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Procainamide.]
[S02AA12, rifamycin SV, The excretion of Procainamide can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The metabolism of Procainamide can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Procainamide.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Procainamide.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Procainamide can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Procainamide can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03AC12, salmeterol, The serum concentration of Procainamide can be increased when it is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Procainamide can be decreased when combined with Domperidone.]
[C01CA04, dopamine, The serum concentration of Procainamide can be increased when it is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Procainamide can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Procainamide can be decreased when combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Procainamide can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Procainamide.]
[N06AB06, sertraline, The metabolism of Procainamide can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Procainamide.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Procainamide.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Procainamide can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Sodium sulfate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Procainamide.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AB13, talinolol, Procainamide may increase the arrhythmogenic activities of Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Procainamide can be decreased when used in combination with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Procainamide can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Procainamide may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Procainamide may increase the arrhythmogenic activities of Tertatolol.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be decreased when used in combination with Procainamide.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Procainamide.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06BA09, atomoxetine, The metabolism of Procainamide can be decreased when combined with Atomoxetine.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Procainamide.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01AA12, tigecycline, The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Procainamide.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Procainamide.]
[H02CA01, trilostane, The therapeutic efficacy of Procainamide can be decreased when used in combination with Trilostane.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Procainamide.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Procainamide.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Procainamide.]
[L01CA04, vinorelbine, The metabolism of Procainamide can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Procainamide may increase the neuromuscular blocking activities of Ephedrine.]
[S01GX10, epinastine, The metabolism of Procainamide can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Procainamide can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, Procainamide may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Procainamide may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Procainamide can be increased when it is combined with Epinephrine.]
[N05CF02, zolpidem, The metabolism of Procainamide can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Procainamide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Iloprost.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Procainamide.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Procainamide.]
[L03AX05, pidotimod, Pidotimod may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Procainamide.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Procainamide can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The serum concentration of Procainamide can be increased when it is combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Procainamide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Procainamide can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Procainamide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Procainamide.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Procainamide.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01XA06, ethylmorphine, The metabolism of Procainamide can be decreased when combined with Ethylmorphine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AE03, sertindole, The metabolism of Procainamide can be decreased when combined with Sertindole.]
[C01BA05, ajmaline, Procainamide may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Procainamide.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Procainamide.]
[R06AX11, astemizole, The metabolism of Procainamide can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Procainamide can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Procainamide can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Procainamide can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Procainamide may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Procainamide may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Procainamide.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Procainamide.]
[M01CB01, gold sodium thiomalate, Sodium aurothiomalate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B05AA05, dextran, Dextran may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Procainamide can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Procainamide.]
[C08EA01, fendiline, Procainamide may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Procainamide can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Procainamide.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Procainamide.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Procainamide.]
[N07AX03, cevimeline, The metabolism of Procainamide can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BC04, flecainide, Procainamide may increase the arrhythmogenic activities of Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fludrocortisone.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[D07XB01, flumethasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Flumethasone.]
[N07CA03, flunarizine, Procainamide may increase the arrhythmogenic activities of Flunarizine.]
[D07AC08, fluocinonide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluocinonide.]
[H02AB03, fluocortolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Procainamide.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01CB05, fluorometholone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Procainamide.]
[N06AB03, fluoxetine, The serum concentration of Procainamide can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Procainamide can be decreased when combined with Fluphenazine.]
[N05CD01, flurazepam, The serum concentration of Procainamide can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AG01, fluspirilene, Procainamide may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01BC03, tegafur, Tegafur may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Procainamide.]
[J05AE10, darunavir, The metabolism of Procainamide can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procainamide.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Procainamide.]
[N06DA04, galantamine, The metabolism of Procainamide can be decreased when combined with Galantamine.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Procainamide.]
[C08DA02, gallopamil, Procainamide may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, The excretion of Procainamide can be decreased when combined with Ganciclovir.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Procainamide.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Procainamide.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Procainamide.]
[N03AD03, methsuximide, Procainamide may increase the arrhythmogenic activities of Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Procainamide.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The metabolism of Procainamide can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Procainamide.]
[C02CA04, doxazosin, The metabolism of Procainamide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Procainamide.]
[M01CB04, aurothioglucose, Aurothioglucose may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Procainamide.]
[P01BX01, halofantrine, The metabolism of Procainamide can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Procainamide.]
[N05AH04, quetiapine, The metabolism of Procainamide can be decreased when combined with Quetiapine.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01CE02, irinotecan, Procainamide may increase the neuromuscular blocking activities of Irinotecan.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Procainamide.]
[B05CB03, magnesium citrate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium citrate.]
[A12CC03, magnesium gluconate, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium gluconate.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Procainamide.]
[J05AG01, nevirapine, The metabolism of Procainamide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Procainamide may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Procainamide may increase the arrhythmogenic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Procainamide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R05DA03, hydrocodone, The metabolism of Procainamide can be decreased when combined with Hydrocodone.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Procainamide can be decreased when used in combination with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04BD06, propiverine, Propiverine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The metabolism of Procainamide can be decreased when combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Hydroxyethyl Starch may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Hydroxyzine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Procainamide.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B05XA08, sodium acetate, Sodium acetate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Procainamide can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AA02, imipramine, The metabolism of Procainamide can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Procainamide.]
[R01AD07, tixocortol, The therapeutic efficacy of Procainamide can be decreased when used in combination with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Procainamide.]
[L01CE01, topotecan, The excretion of Procainamide can be decreased when combined with Topotecan.]
[C03BA11, indapamide, Indapamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A11HA07, inositol, Inositol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX17, milnacipran, Milnacipran may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AA30, piperidolate, The therapeutic efficacy of Piperidolate can be decreased when used in combination with Procainamide.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Procainamide is combined with Cyclopentamine.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Procainamide.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Procainamide.]
[C10AA06, cerivastatin, The metabolism of Procainamide can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Procainamide.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Procainamide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, The metabolism of Procainamide can be decreased when combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Procainamide.]
[N06AF05, iproniazid, The metabolism of Procainamide can be decreased when combined with Iproniazid.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Procainamide.]
[N04BX02, entacapone, The metabolism of Procainamide can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AX05, inosine pranobex, Inosine pranobex may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Procainamide.]
[N06AX18, reboxetine, The metabolism of Procainamide can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Kanamycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Procainamide.]
[L04AC07, tocilizumab, The metabolism of Procainamide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Procainamide can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The excretion of Procainamide can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Procainamide can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AA24, abatacept, The metabolism of Procainamide can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Procainamide.]
[N04BC09, rotigotine, The metabolism of Procainamide can be decreased when combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Procainamide.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AG01, labetalol, The metabolism of Procainamide can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The serum concentration of Procainamide can be increased when it is combined with Amantadine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Procainamide.]
[C08EX01, lidoflazine, Procainamide may increase the arrhythmogenic activities of Lidoflazine.]
[J01FF02, lincomycin, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Lincomycin.]
[S01AA21, amikacin, Amikacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03DB01, amiloride, The serum concentration of Procainamide can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, The metabolism of Procainamide can be decreased when combined with Lisuride.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Procainamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Procainamide can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Procainamide.]
[L01EG01, temsirolimus, The metabolism of Procainamide can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Magnesium chloride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A12CC10, magnesium oxide, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Procainamide.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AA21, maprotiline, The metabolism of Procainamide can be decreased when combined with Maprotiline.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AE05, meclizine, The metabolism of Procainamide can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01AA08, medigoxin, Procainamide may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Procainamide.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AB04, mephenytoin, The metabolism of Procainamide can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Procainamide.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AC03, mesoridazine, The metabolism of Procainamide can be decreased when combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Procainamide can be decreased when combined with Paliperidone.]
[A10BA02, metformin, The excretion of Procainamide can be decreased when combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Procainamide can be decreased when combined with Dolasetron.]
[J01AA05, methacycline, The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Procainamide.]
[N07BC02, methadone, The metabolism of Procainamide can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The metabolism of Procainamide can be decreased when combined with Metamfetamine.]
[A03AB07, methantheline, The therapeutic efficacy of Methantheline can be decreased when used in combination with Procainamide.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Procainamide.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Procainamide can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Pemetrexed may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02BG08, ziconotide, Procainamide may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The metabolism of Procainamide can be decreased when combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Procainamide can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CG05, methylene blue, The metabolism of Procainamide can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Procainamide can be decreased when used in combination with Methylprednisolone aceponate.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03FA01, metoclopramide, The metabolism of Procainamide can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Procainamide.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Procainamide.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Procainamide.]
[N06AX03, mianserin, The metabolism of Procainamide can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Procainamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Procainamide can be decreased when combined with Aminophenazone.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G03XB01, mifepristone, The metabolism of Procainamide can be decreased when combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Procainamide.]
[N06BA12, lisdexamfetamine, The metabolism of Procainamide can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01BD01, amiodarone, The serum concentration of Procainamide can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Procainamide can be decreased when combined with Amitriptyline.]
[A04AA05, palonosetron, The metabolism of Procainamide can be decreased when combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Procainamide can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Procainamide can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Procainamide.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Procainamide.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Procainamide.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Procainamide.]
[N06AA17, amoxapine, The metabolism of Procainamide can be decreased when combined with Amoxapine.]
[C07AA12, nadolol, Procainamide may increase the arrhythmogenic activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Procainamide.]
[L04AC03, anakinra, The metabolism of Procainamide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Procainamide can be decreased when combined with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX21, duloxetine, The metabolism of Procainamide can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Procainamide.]
[S03AA01, neomycin, Neomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Procainamide.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Procainamide can be decreased when combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01AA23, netilmicin, Netilmicin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Procainamide can be decreased when combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Procainamide can be decreased when combined with Niacin.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Procainamide.]
[C04AE02, nicergoline, The metabolism of Procainamide can be decreased when combined with Nicergoline.]
[N07BA01, nicotine, The serum concentration of Procainamide can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, Procainamide may increase the arrhythmogenic activities of Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Procainamide.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Procainamide.]
[C08CA08, nitrendipine, Procainamide may increase the arrhythmogenic activities of Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C01CA03, norepinephrine, The serum concentration of Procainamide can be increased when it is combined with Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Procainamide.]
[N06AA10, nortriptyline, The metabolism of Procainamide can be decreased when combined with Nortriptyline.]
[G02CA02, nylidrin, Procainamide may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Procainamide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Procainamide.]
[L04AC04, rilonacept, The metabolism of Procainamide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Procainamide can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Procainamide can be decreased when combined with Opium.]
[G04CA02, tamsulosin, The metabolism of Procainamide can be decreased when combined with Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Procainamide can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Procainamide.]
[C07AA02, oxprenolol, Procainamide may increase the arrhythmogenic activities of Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Procainamide can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Procainamide can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Procainamide.]
[S01AA04, oxytetracycline, The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Procainamide.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Procainamide.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Procainamide can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Asenapine.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Procainamide.]
[J04AB30, capreomycin, Capreomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Procainamide.]
[H02AB05, paramethasone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Procainamide.]
[G04BD11, fesoterodine, The metabolism of Procainamide can be decreased when combined with Fesoterodine.]
[C07AA23, penbutolol, The metabolism of Procainamide can be decreased when combined with Penbutolol.]
[N05AG03, penfluridol, Procainamide may increase the arrhythmogenic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Procainamide.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XX08, pentostatin, Pentostatin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08EX02, perhexiline, Procainamide may increase the arrhythmogenic activities of Perhexiline.]
[N05AB03, perphenazine, The metabolism of Procainamide can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Procainamide can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A10BA01, phenformin, The metabolism of Procainamide can be decreased when combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Procainamide.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Procainamide.]
[C04AX02, phenoxybenzamine, The serum concentration of Procainamide can be increased when it is combined with Phenoxybenzamine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N03AB02, phenytoin, The metabolism of Procainamide can be decreased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Procainamide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Procainamide.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C08CX01, mibefradil, Procainamide may increase the arrhythmogenic activities of Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Procainamide is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Procainamide can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The metabolism of Procainamide can be decreased when combined with Pindolol.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Atorvastatin.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Procainamide can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Procainamide can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Procainamide can be decreased when combined with Pipotiazine.]
[N06BX03, piracetam, Piracetam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Procainamide.]
[A02BX03, pirenzepine, The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Procainamide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Procainamide.]
[N02CX01, pizotyline, The therapeutic efficacy of Pizotifen can be decreased when used in combination with Procainamide.]
[J05AG02, delavirdine, The metabolism of Procainamide can be decreased when combined with Delavirdine.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L04AC08, canakinumab, The metabolism of Procainamide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Procainamide can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Pitavastatin.]
[C07AB01, practolol, Procainamide may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Procainamide may increase the arrhythmogenic activities of Prajmaline.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Procainamide.]
[S03BA02, prednisolone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Procainamide can be decreased when used in combination with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Procainamide.]
[C01DX02, prenylamine, Procainamide may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Procainamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Procainamide.]
[M04AB01, probenecid, The serum concentration of Procainamide can be increased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Procainamide.]
[S01HA05, procaine, Procainamide may increase the neuromuscular blocking activities of Procaine.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Procarbazine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05AB04, prochlorperazine, The metabolism of Procainamide can be decreased when combined with Prochlorperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Procainamide.]
[G03DA04, progesterone, The metabolism of Procainamide can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Procainamide can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Procainamide can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Procainamide.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N05CM06, propiomazine, The therapeutic efficacy of Propiomazine can be decreased when used in combination with Procainamide.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Procainamide.]
[N02AC04, propoxyphene, The metabolism of Procainamide can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Procainamide.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Procainamide.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Procainamide.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Procainamide.]
[N05AX12, aripiprazole, The metabolism of Procainamide can be decreased when combined with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Procainamide.]
[A03AB15, diphemanil, The therapeutic efficacy of Diphemanil can be decreased when used in combination with Procainamide.]
[A03AB09, isopropamide, The therapeutic efficacy of Isopropamide can be decreased when used in combination with Procainamide.]
[S01FA03, methscopolamine, The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Procainamide.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be decreased when used in combination with Procainamide.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Procainamide.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The metabolism of Procainamide can be decreased when combined with Mepyramine.]
[P01BD01, pyrimethamine, The excretion of Procainamide can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The serum concentration of Procainamide can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Procainamide.]
[P01BC01, quinine, The metabolism of Procainamide can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Procainamide can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[J01AA09, rolitetracycline, The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Rolitetracycline.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Procainamide.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Procainamide.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Procainamide can be decreased when combined with Selegiline.]
[J01GB08, sisomicin, Sisomicin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sodium fluoride may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Procainamide.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
